Clinical Trials

Multiple Myeloma, Recurrence

NCT05455320 2026-04-13

MonumenTAL-3

864 enrolled

Multiple Myeloma, Recurrence

NCT05572515 2026-04-13

MajesTEC-9

614 enrolled

Multiple Myeloma, Recurrence

NCT05519085 2026-03-24

SUCCESSOR-1

Phase 3 Recruiting

810 enrolled

Multiple Myeloma, Recurrence

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

228 enrolled

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT02718833 2026-01-22

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

52 enrolled

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT01562405 2026-01-14

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

33 enrolled

Multiple Myeloma, Recurrence

NCT05922501 2026-01-14

ISABELA

50 enrolled

Multiple Myeloma, Recurrence

NCT07312188 2025-12-31

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

90 enrolled

Multiple Myeloma, Recurrence

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

300 enrolled

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT05911321 2025-10-20

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

6 enrolled

Multiple Myeloma, Recurrence

NCT04176718 2025-10-07

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

43 enrolled

Multiple Myeloma, Recurrence

NCT07018050 2025-09-22

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

160 enrolled

Multiple Myeloma, Recurrence

NCT04191616 2025-09-04

SELECT

54 enrolled 17 charts

Multiple Myeloma, Recurrence

NCT06163040 2025-07-31

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Completed

7 enrolled

Multiple Myeloma, Recurrence

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

265 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT03288974 2025-04-15

Pomalyst PMS

Completed

397 enrolled

Multiple Myeloma, Recurrence

NCT04150965 2025-02-14

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Phase 1/2 Terminated

14 enrolled

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT02406222 2024-12-05

MUKseven

124 enrolled

Multiple Myeloma, Recurrence

NCT02939183 2024-09-26

INTREPID-1

61 enrolled 28 charts

Multiple Myeloma, Recurrence

NCT02616640 2024-09-19

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

114 enrolled

Multiple Myeloma, Recurrence

NCT06232707 2024-05-31

ALUMMINATE

Phase 3 Withdrawn

Multiple Myeloma, Recurrence

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Phase 2 Terminated

45 enrolled

Multiple Myeloma, Recurrence

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

45 enrolled

Multiple Myeloma, Recurrence

NCT01166113 2023-06-29

PCP

67 enrolled

Multiple Myeloma, Recurrence

NCT04895410 2023-03-06

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Phase 1 Terminated

8 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT03439280 2023-02-24

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

50 enrolled 26 charts

Multiple Myeloma, Recurrence

NCT02807454 2023-02-21

FUSIONMM-003

Phase 2 Terminated

37 enrolled 21 charts

Multiple Myeloma, Recurrence

NCT05408026 2023-01-27

Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

Phase 1/2 Withdrawn

Multiple Myeloma, Recurrence

NCT03651128 2022-12-15

KarMMa-3

381 enrolled

Multiple Myeloma, Recurrence

NCT02164955 2022-10-20

A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

Completed

775 enrolled

Multiple Myeloma, Recurrence

NCT05236621 2022-02-11

A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 3 Unknown

85 enrolled

Multiple Myeloma, Recurrence

NCT01712789 2022-01-10

STRATUS

Phase 3 Completed

682 enrolled 23 charts

Multiple Myeloma, Recurrence

NCT03567616 2021-06-30

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2 Terminated

8 enrolled 12 charts

Multiple Myeloma, Neoplasms, Recurrence

NCT01177735 2021-04-22

Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma

71 enrolled 7 charts

Multiple Myeloma, Recurrence

NCT04762745 2021-02-21

The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

56 enrolled

Multiple Myeloma, Recurrence

NCT01497093 2020-04-07

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

34 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

16 enrolled

Disease, Multiple Myeloma, Recurrence, Disease Progression

NCT01324947 2019-11-19

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Phase 3 Completed

74 enrolled 17 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01632826 2019-11-12

PEXIUS

Approved for marketing

Multiple Myeloma, Recurrence

NCT02289222 2019-11-05

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

48 enrolled 10 charts

Multiple Myeloma, Recurrence

NCT02176213 2019-06-18

Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma

35 enrolled

Multiple Myeloma, Recurrence

NCT03601624 2018-11-14

MM-POM-2018

Phase 2 Unknown

18 enrolled

Multiple Myeloma, Recurrence, Disease Progression

NCT01311687 2018-10-24

NIMBUS

Phase 3 Completed

455 enrolled 38 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT03023527 2018-05-23

Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma

Phase 1 Terminated

6 enrolled

Multiple Myeloma, Recurrence

NCT02103335 2017-11-22

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

38 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02046915 2017-10-30

PERSPECTIVE

60 enrolled

Multiple Myeloma, Recurrence

NCT01432600 2017-05-23

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

80 enrolled 12 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02578121 2017-01-23

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

Phase 2 Withdrawn

Multiple Myeloma, Recurrence

NCT02011113 2016-11-01

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

36 enrolled 18 charts